Cancer Genetics Company Profile (NASDAQ:CGIX)

Analyst Ratings

Consensus Ratings for Cancer Genetics (NASDAQ:CGIX) (?)
Ratings Breakdown: 1 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $15.00 (665.31% upside)

Analysts' Ratings History for Cancer Genetics (NASDAQ:CGIX)
Show:
DateFirmActionRatingPrice TargetActions
3/15/2016AegisBoost Price TargetBuy$8.00 -> $15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/11/2016Janney Montgomery ScottReiterated RatingBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/14/2015Cantor FitzgeraldReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Cancer Genetics (NASDAQ:CGIX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q1($0.43)($0.39)$6.95 million$6.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/10/2016Q415($0.46)($0.48)$7.00 million$5.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.49)($0.56)$5.13 million$4.00 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.50)($0.51)$4.67 million$4.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.54)($0.44)$3.91 million$4.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.50)($0.49)$3.70 million$4.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.51)($0.41)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2014Q214($0.37)($0.50)$2.13 million$3.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/15/2014Q114($0.29)($0.27)$2.17 million$1.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/26/2014Q4 13($0.36)($0.37)$1.95 million$1.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2013Q313($0.71)($0.61)$1.60 million$1.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cancer Genetics (NASDAQ:CGIX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.38)($0.28)($0.33)
Q2 20161($0.33)($0.33)($0.33)
Q3 20161($0.29)($0.29)($0.29)
Q4 20161($0.24)($0.24)($0.24)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cancer Genetics (NASDAQ:CGIX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cancer Genetics (NASDAQ:CGIX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/17/2016John PappajohnDirectorBuy50,000$2.64$132,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2016Panna SharmaCEOBuy1,500$2.59$3,885.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016John PappajohnDirectorBuy100,000$2.53$253,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Panna SharmaCEOBuy1,000$2.56$2,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/27/2015John PappajohnDirectorBuy5,000$9.61$48,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Raju S.K. ChagantiDirectorSell5,296$12.00$63,552.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2015Raju S.K. ChagantiDirectorSell7,000$12.01$84,070.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/11/2015Raju S.K. ChagantiDirectorSell46,454$12.03$558,841.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Raju S.K. ChagantiDirectorSell24,583$12.03$295,733.49View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2015John PappajohnDirectorBuy5,000$10.74$53,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015John PappajohnDirectorBuy50,000$7.36$368,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Edward J SitarCFOBuy1,000$6.99$6,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014John PappajohnDirectorBuy5,589$6.20$34,651.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2014John PappajohnDirectorBuy3,634$6.14$22,312.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/11/2014John PappajohnDirectorBuy27,087$6.03$163,334.61View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2014John PappajohnDirectorBuy5,773$5.96$34,407.08View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2014John PappajohnDirectorBuy39,686$5.35$212,320.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014Edward SitarCFOBuy1,000$10.67$10,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2014John PappajohnDirectorBuy50,000$10.31$515,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cancer Genetics (NASDAQ:CGIX)
DateHeadline
07/23/16 03:08 PMShares Stumbling of Late: Cancer Genetics, Inc. (NASDAQ:CGIX) - TGP
07/22/16 03:05 PMCANCER GENETICS, INC Files SEC form 8-K, Shareholder Director Nominations -
07/22/16 11:20 AMInsiders Increasing Positions in: Cancer Genetics, Inc. (NASDAQ:CGIX) - Press Telegraph
07/22/16 11:20 AMCancer Genetics Inc (NASDAQ:CGIX) Stock Technicals at Critical Inflection Point - CML News
07/19/16 03:13 PMCancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker Discovery and Testing for a Global Drug ... - Yahoo Finance
07/19/16 03:13 PMCancer Genetics, Inc. (NasdaqCM:CGIX) Fundamental Star Rating Report - CML News
07/19/16 11:11 AMETF’s with exposure to Cancer Genetics, Inc. : July 19, 2016 -
07/19/16 09:24 AMSome Traders Are Very Bearish on Cancer Genetics Inc After Forming Bearish Multiple Bottom Chart Pattern - Consumer Eagle
07/19/16 09:24 AMInvestor Watch: Volatility Recap on Shares of: Cancer Genetics, Inc. (NASDAQ:CGIX) - Engelwood Daily
07/17/16 07:49 AMCancer Genetics: 'Warrant,' You Are Under Arrest - Seeking Alpha
07/15/16 12:01 PMCancer Genetics Inc Stock Decreased as Institutional Investors Exit - Consumer Eagle
07/14/16 08:59 AMCancer Genetics Inc Stock Momentum at Critical Inflection Point - CML News
07/14/16 08:59 AMCancer Genetics Incorporated (NASDAQ:CGIX) Shorts Decreased by 9.24% After Short Covering - Consumer Eagle
07/10/16 03:04 PMCancer Genetics Incorporated (NASDAQ:CGIX) Short Interest Decreased By 9.24% - Engelwood Daily
07/07/16 03:12 PMCould Cancer Genetics Inc Rise Even More? The Stock Had Another Big Increase Today - Press Telegraph
07/02/16 10:47 AMCompany Stock Lower on the Week Cancer Genetics, Inc. (NASDAQ:CGIX) - Engelwood Daily
06/30/16 03:25 PMUpdate on Stock Volatility for: Cancer Genetics, Inc. (NASDAQ:CGIX) - Engelwood Daily
06/30/16 03:25 PMCancer Genetics (CGIX) Begins Offering VENTANA PD-L1 as Complimentary IHC Test for TECENTRIQ - StreetInsider.com
06/30/16 03:06 PMCANCER GENETICS, INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits -
06/28/16 08:01 AMStock Volatility in Review: Cancer Genetics, Inc. (NASDAQ:CGIX) - Engelwood Daily
06/27/16 03:05 PMCancer Genetics Names Healthcare Technology Industry Veteran John Jay Roberts as COO and Executive Vice President of Finance
06/27/16 07:46 AMBroker Outlook For The Week Ahead Cancer Genetics, Inc. (CGIX) - Fiscal Standard
06/23/16 04:38 PMCancer Genetics, Inc. (CGIX) Current Analyst Ratings - Fiscal Standard
06/23/16 04:38 PMCancer Genetics (CGIX) Enters Distribution Agreement for TOO Test in India, South Asia - StreetInsider.com
06/23/16 07:25 AMCancer Genetics, Inc. and Sayre Therapeutics Announce Distribution Agreement to Commercialize CGI’s Proprietary FDA-cleared Tissue of Origin (TOO®) Test Throughout India and South Asia - [GlobeNewswire] - TOO ® is the ONLY FDA-cleared test of its type, used to aid in identifying challenging tumors, including metastatic, poorly differentiated, and undifferentiated cancers The partnership will leverage Sayre’ ...
06/19/16 03:02 PMThis Weeks Broker Views For Cancer Genetics, Inc. (CGIX) - Fiscal Standard
06/07/16 06:30 AMCancer Genetics, Inc. to Present at the 2016 LD Micro Invitational Investor Conference - [GlobeNewswire] - RUTHERFORD, N.J., June 07, 2016-- Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and ...
06/06/16 07:08 AMHTG Molecular Diagnostics and Cancer Genetics Announce Presentation of an Immuno-Oncology Study at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting - [at noodls] - TUCSON, Ariz. and LOS ANGELES, June 06, 2016 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) ('HTG'), a provider of instruments and reagents for molecular profiling applications, and ...
06/03/16 11:49 AMBroker Analysis: Cancer Genetics, Inc. (CGIX) - Share Trading News
05/31/16 07:35 AMGenetic Testing For Cancer Risk Is On The Rise But Is It Smart? -
05/27/16 01:05 PMCancer Genetics, Inc. (CGIX) Updated Price Targets - FTSE News - Cancer Genetics, Inc. (CGIX) Updated Price TargetsFTSE NewsCancer Genetics, Inc. has a 50 day moving average of 2.48 and a 200 day moving average of 2.69. The stock's market capitalization is 29.08M, it has a 52-week low of 1.90 and a 52-week high of 12.75. The share price of the company (CGIX) was down ...Cancer Genetics, Inc (CGIX) Files Form 4 Insider Buying : John Pappajohn Buys 317820 SharesMarket Digestall 2 news articles »
05/26/16 12:08 PMHold Calls Count For Cancer Genetics, Inc. (NASDAQ:CGIX) At 0 - RealistInvestor.com - Hold Calls Count For Cancer Genetics, Inc. (NASDAQ:CGIX) At 0RealistInvestor.comBuy calls count on Cancer Genetics, Inc. (NASDAQ:CGIX)'s stock stands at 0 while Sell recommendations is 0. Hold recommendation is 0. Cancer Genetics, Inc. (NASDAQ:CGIX) has a total of 2 Strong Buy recommendations and 0 Strong Sell advises as of ...and more »
05/23/16 12:12 PMCancer Genetics, Inc. :CGIX-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 -
05/21/16 11:39 AMRevenue Update on Cancer Genetics Inc(NASDAQ:CGIX) - Trade Calls - Revenue Update on Cancer Genetics Inc(NASDAQ:CGIX)Trade CallsCancer Genetics Inc(NASDAQ:CGIX) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during After-hours on May 10, 2016. Company reported revenue of $6.07M. Analysts estimated a revenue of $6.95M. Earnings per share ...Unusual Volume Watch: Cancer Genetics, Inc. (NASDAQ:CGIX)The PostLatest Analyst Ratings For Cancer Genetics, Inc. (CGIX)Share Trading NewsCancer Genetics (CGIX) Announces $5M Registered Direct OfferingStreetInsider.comWall Street Hints and News -Sonoran Weekly Review -Seeking Alphaall 10 news articles »
05/20/16 12:03 PMCancer Genetics Announces $5 Million Registered Direct Offering - RUTHERFORD, N.J., May 20, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("Cancer Genetics" or the "Company"), an emerging leader in DNA-based cancer diagnostics, today announced that it has entered into definitive agreements with healthcare ...
05/20/16 08:09 AMCANCER GENETICS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defini -
05/19/16 11:41 AMInsiders Are Buying Cancer Genetics, Inc. (NASDAQ:CGIX) - Wall Street Hints and News - Insiders Are Buying Cancer Genetics, Inc. (NASDAQ:CGIX)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Cancer Genetics, Inc. (NASDAQ:CGIX) have increased their position in the stock by 8.20%. Insiders now own 14.20% of total outstanding shares. There are both legal and illegal types of insider trading.and more »
05/17/16 12:38 PMCancer Genetics, Inc. (NASDAQ:CGIX) Quarterly EPS Projection At $-0.29 - Investor Newswire - Cancer Genetics, Inc. (NASDAQ:CGIX) Quarterly EPS Projection At $-0.29Investor NewswireA week earlier, the EPS projection was $-0.29 while 30-days ago it was $-0.29. This target was set at $-0.29 60 days ago and it was $-0.29 90 days earlier. From a week ago, the change in estimates is -0.14%. EPS was revised 1 times up and 1 down in ...and more »
05/17/16 06:30 AMCancer Genetics, Inc. Launches The Most Comprehensive & Clinically Actionable Next Generation Sequencing Panel in Precision Medicine, FOCUS::Lymphoma ™ - [GlobeNewswire] - FOCUS:: Lymphoma™ panel is being used to power several clinical trials with biotech and pharmaceutical companies, and is now available for use in a clinical setting FOCUS:: Lymphoma™ can be personalized ...
05/13/16 06:13 AMCancer Genetics: Still A Broke'n' Company - Seeking Alpha - Seeking AlphaCancer Genetics: Still A Broke'n' CompanySeeking AlphaLast month, I penned an article titled, Cancer Genetics: Unless Cash Flows Improve, More Dilution May Come Next. This piece is a continued analysis of the issues raised in that article. I was previously bullish on Cancer Genetics, Inc. (NASDAQ:CGIX).
05/10/16 03:26 PMCancer Genetics reports 1Q loss -
05/10/16 03:09 PMCANCER GENETICS, INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Fin -
05/10/16 03:04 PM4:04 pm Cancer Genetics beats by $0.04, misses on revs -
05/10/16 03:01 PMCancer Genetics, Inc. Announces 39% Revenue Increase and Provides Recent Company Highlights - [GlobeNewswire] - Company reports record quarterly revenues of $6.1 million, an increase of 39% over Q1 2015 and 11% over Q4 2015 Significant expansion of new Immuno-Oncology test offering, with expansion into 12 active ...
05/10/16 06:07 AMQ1 2016 Cancer Genetics Inc Earnings Release - After Market Close -
05/06/16 06:10 AMIs Selling Cancer Genetics Inc Here a Winning Strategy? - B.O.D.Y Confidential - Is Selling Cancer Genetics Inc Here a Winning Strategy?B.O.D.Y ConfidentialThe stock of Cancer Genetics Inc (NASDAQ:CGIX) is a huge mover today! The stock decreased 9.69% or $0.25 on May 5, hitting $2.33. About 78,551 shares traded hands. Cancer Genetics Inc (NASDAQ:CGIX) has declined 70.20% since September 30, 2015 ...
05/06/16 06:10 AMCancer Genetics (CGIX) Actively Testing, Providing Data for 12 IO Clinical Trials, 3 Academic Collaborations - StreetInsider.com - Cancer Genetics (CGIX) Actively Testing, Providing Data for 12 IO Clinical Trials, 3 Academic CollaborationsStreetInsider.comCancer Genetics, Inc. (Nasdaq: CGIX) announced that the company is actively testing and providing data for 12 Immuno-Oncology (IO) clinical trials and 3 academic collaborations. The trials focus on solid tumors including lung, ovarian, head and neck ...Cancer Genetics Expands Market Share In Immuno-Oncology Focused Clinical StudiesBenzingaall 2 news articles »
05/05/16 06:14 AMCancer Genetics, Inc. to Present at Pioneers 2016 Conference Presented by Joseph Gunnar & Co., LLC - [GlobeNewswire] - RUTHERFORD, N.J., May 05, 2016-- Cancer Genetics, Inc., a leader in enabling precision medicine for oncology through molecular markers and diagnostics, announced today that Panna Sharma, President and ...
05/05/16 06:03 AMCancer Genetics Expands Market Share In Immuno-Oncology Focused Clinical Studies - Benzinga - Cancer Genetics Expands Market Share In Immuno-Oncology Focused Clinical StudiesBenzingaCancer Genetics, Inc. CGIX 4.08% revealed it was actively testing and providing data for 12 Immuno-Oncology (IO) clinical trials and three academic collaborations. As a result, it was expanding its market share in the field. According to the company ...Cancer Genetics, Inc. Significantly Expands Marketshare In Immuno-Oncology Focused Clinical Trials With 12 Active ...Investing News Network (press release) (registration) (blog)all 2 news articles »
05/05/16 06:03 AMLatest Analyst Ratings For Cancer Genetics, Inc. (CGIX) - Share Trading News - Latest Analyst Ratings For Cancer Genetics, Inc. (CGIX)Share Trading NewsCancer Genetics, Inc. has a 50 day moving average of 2.72 and a 200 day moving average of 3.13. The stock's market capitalization is 27.48M, it has a 52-week low of 1.90 and a 52-week high of 12.75. The share price of the company (CGIX) was up +5.31%, ...Cancer Genetics Incorporated (NASDAQ:CGIX) Shorted Shares Decreased By 12.14%B.O.D.Y Confidentialall 2 news articles »

Social

About Cancer Genetics

Cancer Genetics logoCancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic products and services, and molecular markers. The Company develops, commercializes and provides molecular- and biomarker-based tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. Its molecular- and biomarker-based diagnostic services are provided for three sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CGIX
  • CUSIP:
Key Metrics:
  • Previous Close: $2.04
  • 50 Day Moving Average: $2.03
  • 200 Day Moving Average: $2.34
  • P/E Ratio: N/A
  • P/E Growth: -0.04
  • Market Cap: $26.76M
  • Beta: 1.12
  • Current Year EPS Consensus Estimate: $-1.26 EPS
  • Next Year EPS Consensus Estimate: $-0.42 EPS
Additional Links:
Cancer Genetics (NASDAQ:CGIX) Chart for Saturday, July, 30, 2016